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doi:10.1016/j.jtcvs.2006.08.042bjective: Economists have designed frameworks to measure the economic value of
mprovements in health and longevity. Heart valve replacement surgery has signif-
cantly prolonged life expectancy and quality of life. For the example of aortic valve
eplacement, what is its economic value according to this framework?
ethods: From 1961 through 2003, a total of 4617 adult patients underwent aortic
alve replacement by one team of cardiac surgeons. These patients were provided
ith a prospective lifetime follow-up service. As of 2005, observed follow-up was
1,671 patient-years, with a maximum of 41 years. A statistical model was used to
enerate the future life-years of patients currently alive. The value of life-years
roposed by economists was applied to determine the economic value of the
dditional life given to these patients by aortic valve replacement.
esults: The total life-years after aortic valve replacement were 53,323, with a gross
alue of $14.6 billion. The total expected life-years without surgery were 10,157,
ith an estimated value of $3.0 billion. Thus the net life-years gained by AVR were
3,166, worth $11.6 billion. Subtracting the $451 million total lifetime cost of
urgery, the net value of the life-years gained by AVR was $11.2 billion. The mean
et value decreases according to age at surgery but is still worth $600,000 for
ctogenarians and $200,000 for nonagenarians.
onclusion: According to the economic concept of the value of a statistical life, the
eturn on the investment for aortic valve replacement is enormous for patients of all
ges, even very elderly patients.
he concept and measurement of gross domestic product, for which the 1971
Nobel Prize was awarded, does not take into consideration improvements to
the longevity and health status of the population. Yet from 1900–2000 there
as an increase in life expectancy of 28 years for men and 32 years for women.1
mprovements in the medical and surgical management of heart disease and pre-
entive measures have undoubtedly played a role in the reduction of age-adjusted
eath rates from 559 to 232 deaths per 100,000 per year between 1960 and 2003
Figure 1).2 This reduced mortality from heart disease has produced a value of
bout 1.5 trillion dollars per year, which is not included in the US gross domestic
roduct.3
Economist Kevin M. Murphy was recently recognized by the MacArthur Foun-
ation (the “genius award”) for his work in assessing the value of a statistical life.
n a 2005 article, “The Value of Health and Longevity,” Murphy and Topel3
eveloped a framework for assigning an economic value to improvements to health
nd life expectancy, measuring the value of a single statistical life and the value of
ach year of life. Such valuations are commonly used by regulatory agencies to
etermine the cost-effectiveness of environmental regulations.4 This method has
lso been applied to assess the value of increases to the length and quality of life
aused by medical advances.
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STA
TSThe clinical benefit of heart valve replacement surgery
as been well documented. Our recent study assessed the
ost-effectiveness of aortic valve replacement (AVR), which
as found to be very cost-effective for patients at all ages,
ven very elderly patients.5 In this investigation we used the
ame data to determine the value of AVR, especially for
lderly patients, with this new econometric methodology.
aterials and Methods
rom 1961 through 2003, a total of 4617 patients older than 20
ears underwent AVR on our service at three hospitals in Portland,
re. The mean age at surgery was 65 years; 502 (10.9%) were
ctogenarians and 23 (0.5%) were nonagenarians. Beginning with
he first patient, a prospective lifetime follow-up service was
mplemented. All patients undergoing valve replacement are fol-
owed up at annual intervals with a combination of mailed ques-
ionnaire and telephone interview. The total follow-up was 31,671
atient-years, with a maximum of 41 years.
The value of AVR was calculated in several steps. All calcu-
ations were done at the individual patient level, and the results
ere presented by grouping age at surgery into 5-year intervals. To
acilitate and standardize calculation, all monetary values in the
tudy were adjusted to 2005 dollars with yearly inflation factors
btained from the consumer price index compiled by the US Bureau
f Labor Statistics (http://inflationdata.com/Inflation/Inflation_Rate/
istoricalInflation.aspx).
Abbreviations and Acronyms
AVR aortic valve replacement
igure 1. Age-adjusted death rates by major cause of death,
nited States, 1960-2003. Source data from US National Center for
ealth Statistics.2 Other disease category includes chronic lower
espiratory diseases, diabetes mellitus, influenza, pneumonia,Mhronic liver disease, and cirrhosis.
04 The Journal of Thoracic and Cardiovascular Surgery ● MarcStep 1: Determine the value of a life-year (economic
ramework). Economists Murphy and Topel3 developed an eco-
omic framework for assigning a dollar amount to improvements
o health and life expectancy, measuring the value of a single
tatistical life and the value of each year of life. This work
ndicates that the relationship between the value of a life-year and
ge is characterized by an inverted U–shaped curve, which peaks
round age 50. These published estimates were converted from
000 dollars to 2005 dollars with the inflation factors (Figure 2).
Step 2: Determine survival after AVR. Survival after
VR was determined from the observed data from our follow-up
ystem and completion of the currently censored lifetimes with a
ompertz regression model derived from the observed patient
ata, as previously described.5 Gompertz regression has been
idely used to model survival time in survival analysis, especially
or elderly persons.6 The simulation was repeated 1000 times, and
he mean was used in the final calculation.
Step 3: Determine survival of patients with aortic valve
isease not operated on (natural history). Mean survival of
atients with severe aortic valve disease not operated on was
pproximately 2.2 years, as determined by a previously described
iterature review.5
Step 4: Cumulative years of survival after AVR by
atient age. The value of a life-year proposed by Murphy and
opel3 is dependent on an individual’s age, so for each year a
atient lived after AVR a dollar value was assigned according to
ge in that year. For example, a patient who had AVR at age 69.4
ears and lived 5.0 years would contribute 0.6 year to age 69 years,
year each to ages 70, 71, 72, and 73 years, and 0.4 year to age
4 years. This calculation was repeated for every patient, and the
esults were added to obtain the total life-years at different ages
fter AVR.
Step 5: Cumulative years of survival of patients with
evere aortic valve disease not operated on by patient
ge. The average survival for unoperated aortic valve disease was
.2 life-years. The patient in the previous example thus would have
igure 2. Value of life-year by age in 2005 dollars, as derived from
urphy and Topel.3
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A
TSived 2.2 years without operation. He would contribute 0.6 year to
ge 69 years, 1 year to age 70 years, and 0.6 year to age 71 years.
he same calculation was repeated for every patient, and the
esults were summed to obtain the total life-years at different ages
ithout operation.
Step 6: Net life-years gained from AVR. For each patient,
ife-years gained by AVR were calculated as the life-years after
VR (step 4) minus the life-years with unoperated heart valve
isease (step 5). Note that not all individual patients benefited from
VR. Those who lived for a shorter time than expected, for
xample patients with a surgically related death, contributed a
egative amount to the total gain from surgery. Total life-years
ained by AVR was obtained by summing the life-years gained by
ach patient.
Step 7: Economic value of life-years gained by AVR. For
ach patient the value of life-years gained was calculated by
umming the value of a life-year at each year of age defined by the
conomic framework (step 1, Figure 2). The value of life-years
ained by each patient was summed to get the total value of
ife-years gained after AVR. For the example in step 4, the value
f life years after AVR would be (0.6  $299,000)  $285,000 
279,000  $265,000  $255,000  0.4  $247,000  $1.36
illion, and the value of the natural history would be (0.6 
299,000)  $285,000  (0.6  $279,000)  $0.63 million. The
alue gained by AVR would be $0.73 million for the patient.
Step 8: Net value of AVR. The lifetime costs of AVR (cost
f the original surgery, of ongoing maintenance, and of treating
alve-related complications) were calculated as described previ-
usly.5 The net value of AVR by age at surgery was obtained by
ubtracting the lifetime cost from the value of life-years gained
step 7).
esults
urvivals (mean  SE) after AVR were 50%  0.9%,
igure 3. Total life-years after aortic valve replacement (light
ray bar) and natural history (dark gray bar) by age at surgery.
VR, aortic valve replacement.0%  1.0%, 6.8%  0.8%, and 3.9%  0.8% at 10, 20, m
The Journal of Thoracic0, and 40 years, respectively. For the 2382 patients who
ied, a total of 17,525 follow-up years were observed. For
he 2235 patients with censored data, a total of 14,146
ollow-up years were documented, and an additional 21,652
ears were imputed from the regression model.
The total life-years after AVR were 53,323 (total area of
he light gray bars, including the part covered by the dark
ray bars, in Figure 3). The total expected life-years without
urgery were 10,157 (area of the dark gray bars superim-
osed on the light gray bars in Figure 3). The difference
etween the light and dark gray bars (the visible light gray
rea), 43,166 years, represents the total life-years gained by
VR. The total value of the life-years after AVR was $14.6
illion; the total value of the expected life-years without
urgery was $3.0 billion. Thus the value of life-years gained
y AVR was $11.6 billion. After deduction of the lifetime
ost of $451 million, the net value of AVR was $11.2
illion. Figure 4 shows the average net value of AVR by age
t surgery. The mean net value decreases according to age
t surgery but is still worth $600,000 for octogenarians and
200,000 for nonagenarians.
iscussion
e previously showed AVR to be very cost-effective5
ccording to generally accepted thresholds,7,8 even for very
lderly patients. These thresholds, however, are arbitrary.
conomists have developed a framework for assigning an
conomic value to a life-year. In this study we evaluated the
alue of AVR with this new concept.
The enormous value of AVR ($11.6 billion) compared with
ts cost ($451 million) is noteworthy and surprising. The
igure 4. Average net value gained after aortic valve replace-
ent by age at surgery (gray bar). Error bars indicate 95% range
rom 1000 times simulation. AVR, aortic valve replacement.ethod used, however, was based on established economic
and Cardiovascular Surgery ● Volume 133, Number 3 605
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STA
TSnalysis. Although the exact value used is a source of debate
mong economists, there is an agreement that the true value is
degree of magnitude greater than the traditional valuations
hat are based only on future lifetime earnings. Several
ethods have been devised to estimate this value.
One method uses consumer market analysis. We all
urchase items that reduce our risk of dying (fire alarm,
utomobile airbags, bicycle helmet, etc). Suppose there is a
isk of 1 in 10,000 of death from a certain cause. In a group
f 10,000 people, 1 such death would be expected. Suppose
here is an item that eliminates that risk, and the market
alue of that item is $500. If all 10,000 people in that group
urchased the item, 1 “statistical death” would be prevented
t a total cost of $5 million. That figure could then be taken
s the value of a “statistical life.”
Another method uses labor market analysis. Suppose that
wo jobs, A and B, are similar except that B includes a
azardous duty component that adds a 1 in 1000 risk of
atality. Because of that higher risk, job B pays $5000 more.
y multiplication, 1 whole fatality would be “worth” 1000
imes $5000, or $5 million. This is the method used by
urphy and Topel,3 whose article on this subject was used
or our cost estimates. There are other sources addressing
his subject and its limitations,9-14 including some easy-to-
ead articles or books on the subject by Murphy and Topel9
nd David Cutler.13,14
Murphy and Topel3 estimated the value of a statistical
ife at $6.3 million in 2000 dollars between ages 25 and 55.3
hat value was based on research results from the US
nvironmental Protection Agency, which gave a range of
5.5 to $7.6 million in 2000 dollars.4 Other analyses and
eta-analyses have come up with different values, but all
re within the same order of magnitude (the following are in
illions of 2005 dollars): $1.8 to $3.0,15 $1.1 to $3.6,16 $2.6
o $4.7,17 $2.9 to $15.3,18 $2.9 to $11.2,19 $4.5 to $10.5,20
7.7,21 $3.6 to $10.9,22 and $7.2.11 Because our study is the
rst venture into this new area, we only provided the point
stimates based on Murphy and Topel’s work.3 The next
tep of investigation would be doing sensitivity analysek
nd adding confidence intervals to the estimates.
The value of AVR arrived at by this study considered
nly the extended life-years of our patients relative to their
xpected lifetimes if not operated on. These extra years also
ave a higher quality than exists with the natural history of
he disease.5 A monetary value could also be attached to this
mprovement in quality of life. There is no published evi-
ence, however, that persons with physical limitations or
hronic illnesses are willing to pay less to increase their
ongevity than are persons without these limitations.23,24
e deducted the lifetime cost of AVR but did not add the
osts of caring for patients with severe unoperated disease.
ad this aspect also been considered, the value attached to
VR would have been slightly higher.
1
06 The Journal of Thoracic and Cardiovascular Surgery ● MarcThe candidates for AVR are getting older and sicker.
lderly patients undergoing AVR have achieved satisfac-
ory results in terms of both long-term survival and quality
f life. The length of the study crossed 4 decades, during
hich there were changes in patient profile, surgical tech-
ique, and health care policy. We have been operating on
ctogenarians since the 1980s and on nonagenarians since
he 1990s. Physicians may still be hesitant to recommend
lderly patients for surgical therapy merely on the basis of
linical outcome, because cardiac valve surgery in elderly
atients is associated with higher resource use in light of
heir limited life expectancy. Even considering lifetime
osts and changing patient profiles, however, the value of
VR is still tremendous for all time periods (the graphs for
ifferent time periods were similar, results not shown), even
or elderly patients, according to this economic concept.
This report provides an insight into the enormous eco-
omic value of effective medical therapy, with AVR as an
xample. It is to be hoped that this methodology will be
pplied to other therapies in the future as a guide to the most
ffective medical care.
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